MK 826

Known as: MK-826 
 
National Institutes of Health

Topic mentions per year

Topic mentions per year

1998-2002
012319982002

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2002
Review
2002
Ertapenem sodium (trade name Invanz, also designated as MK-0826, MK-826 and L-749345), manufactured by Merck & Co., Inc. is a… (More)
Is this relevant?
Review
2001
Review
2001
Beta-lactam antibiotics represent the most commonly prescribed antibacterial agents. New beta-lactams have been introduced… (More)
Is this relevant?
2000
2000
The activity of MK-826 was compared to the activities of cefoxitin, ceftriaxone, imipenem, and meropenem against 363 gram… (More)
Is this relevant?
Review
2000
Review
2000
During the last few decades, several carbapenems have been developed. The major characteristic of the newer drugs, such as MK-826… (More)
Is this relevant?
2000
2000
  • P. S. Carlson
  • European Journal of Clinical Microbiology and…
  • 2000
In summary, PNU-100766, RP-59500 and LY-333328 displayed the highest level of antimicrobial efficacy against gram-positive… (More)
  • table 1
  • table 2
Is this relevant?
1999
1999
After intravenous administration of MK-826, a new carbapenem antibiotic, the compound exhibited nonlinear pharmacokinetics in… (More)
Is this relevant?
1998
1998
MK-826 (formerly L-749,345), is a potent 1-beta-methyl carbapenem with a long half-life and broad spectrum of activity. This… (More)
Is this relevant?